OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Saxena on Shifts in Treatment With Targeted and Immune Therapies in NSCLC

April 19th 2024

Ashish Saxena, MD, PhD, discusses recent shifts in treatment with the use of targeted and immune therapies in non–small cell lung cancer.

Dr Tiwari on Optimal Treatment Sequencing in HER2+ Breast Cancer

April 19th 2024

Shruti Tiwari, MD, discusses treatment sequencing in HER2+ breast cancer, highlighting how to treat these patients when they present with CNS involvement.

Dr Kopetz on Adagrasib Plus Cetuximab in KRAS G12C+ mCRC

April 19th 2024

Scott Kopetz, MD, PhD, FACP, discusses the clinical efficacy and safety of adagrasib plus cetuximab in patients with KRAS G12C-mutated mCRC.

Dr Hoebel on Modeling Spatial Interactions to Predict Outcomes in NSCLC

April 19th 2024

Katharina Hoebel, MD, PhD discusses the efficacy of incorporating spatial interactions within predictive models, in the realm of oncology.

Dr Coombs on Disease Management Strategies in AML

April 18th 2024

Catherine C. Coombs, MD, discusses strategies for disease classification and management for patients with acute myeloid leukemia.

Dr Adjei on the Rationale for Opportunistic Salpingectomy for Ovarian Cancer Prevention

April 18th 2024

Naomi Adjei, MD, MPH, MSEd, discusses an analysis of the cost-effectiveness of opportunistic salpingectomy for the primary prevention of ovarian cancer.

Dr Kirkwood on the Evolving Treatment of Resected Melanoma

April 18th 2024

John M. Kirkwood, MD, discusses the significance of the FDA approval of adjuvant nivolumab for patients with resected stage IIB or IIC melanoma.

Dr Tannir on Unmet Needs in the Treatment of Rare Kidney Tumors

April 18th 2024

Nizar M. Tannir, MD, FACP, discusses unmet needs for patients with rare kidney tumors and how these needs may be addressed in the future.

Dr Pearse on the Current Treatment Paradigm for Relapsed/Refractory MCL

April 18th 2024

William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.

Dr Olson on Toxicities Associated With Lifileucel and IL-2 in Melanoma

April 18th 2024

Daniel Olson, MD, discusses toxicities associated with lifileucel and IL-2 in patients with unresectable or metastatic melanoma.

Dr Chen on the Investigation of CDK4/6 Inhibitors in Early-Stage Breast Cancer

April 18th 2024

Nan Chen, MD, discusses the investigation of CDK4/6 inhibitors in early-stage breast cancer.

Dr Dreicer on the Different Approaches to mCRPC Management

April 18th 2024

Robert Dreicer, MD, discusses different approaches in prostate cancer management according to the type of oncologist.

Dr Jain on the Long-Term Investigation of Luspatercept in Anemic MDS

April 17th 2024

Akriti Jain, MD, discusses updated data from the phase 3 MEDALIST trial evaluating luspatercept for the treatment of anemic myelodysplastic syndromes.

Dr Srour on Toxicities Associated With CAR T-Cell Therapy in RCC and Other Solid Tumors

April 17th 2024

Samer A. Srour, MB ChB, MS, discusses toxicities associated with CTX130 in advanced clear cell renal cell carcinoma.

Dr Kristeleit on the ATHENA-MONO Trial in Ovarian Cancer

April 17th 2024

Rebecca Kristeleit, BSc, MBChB, MRCP, PhD, discusses the phase 3 ATHENA-MONO trial in newly diagnosed patients with advanced ovarian cancer.

Dr Foldi on the Evolving Role of T-DXd in HER2+ Breast Cancer

April 17th 2024

Julia Foldi, MD, PhD, discusses the evolving role of treatment with T-DXd in metastatic HER2-positive breast cancer.

Dr Guerra on a Culturally Tailored Approach to Prostate Cancer Screening Awareness

April 17th 2024

Carmen Guerra MD, MSCE, examines how a culturally sensitive could help raise prostate cancer screening awareness.

Dr Maxwell on a Study of Genetic Testing in Metastatic Prostate Cancer

April 17th 2024

Kara Maxwell, MD, PhD discusses a study of genetic testing results in metastatic prostate cancer.

Dr Sinno on Molecular Characterization in Endometrial Cancer

April 17th 2024

Abdulrahman Sinno, MD, discusses the shift in focus to molecular characteristics of endometrial cancer.

Dr Gatti-Mays on the Use of Neoadjuvant Chemoimmunotherapy in Early-Stage TNBC

April 16th 2024

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses the current use of neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer.